Alterity Therapeutics Confirms Phase 3 Trial Pathway for ATH434
Alterity Therapeutics secures FDA alignment on ATH434’s pivotal Phase 3 trial design, advancing its potential treatment for multiple system atrophy.
Alterity Therapeutics secures FDA alignment on ATH434’s pivotal Phase 3 trial design, advancing its potential treatment for multiple system atrophy.